Lobe Sciences (FRA:LOBE) OCF Margin %: 0.00% (As of Feb. 2026)


What is Lobe Sciences OCF Margin %?

Lobe Sciences FRA:LOBE OCF Margin % is 0.00% as of Feb. 2026. The stock has 2 warning signs investors should review. Among 960 Biotechnology companies, Lobe Sciences ranks worse than 104166.56% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Lobe Sciences's Cash Flow from Operations for the three months ended in Feb. 2026 was €-1.28 Mil. Lobe Sciences's Revenue for the three months ended in Feb. 2026 was €0.00 Mil. Therefore, Lobe Sciences's OCF Margin % for the quarter that ended in Feb. 2026 was 0.00%.

As of today, Lobe Sciences's current OCF Yield % is -15.16%.

The historical rank and industry rank for Lobe Sciences's OCF Margin % or its related term are showing as below:


During the past 13 years, the highest OCF Margin % of Lobe Sciences was -204.40%. The lowest was -339.71%. And the median was -264.08%.

FRA:LOBE's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -68.59
* Ranked among companies with meaningful OCF Margin % only.

Lobe Sciences OCF Margin % Related Terms

Lobe Sciences OCF Margin % Historical Data

* Premium members only.

The historical data trend for Lobe Sciences's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lobe Sciences OCF Margin % Chart

Lobe Sciences Annual Data
Trend Dec16 Dec17 Dec18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24 Aug25
OCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -204.55 -341.11 0.00

Lobe Sciences Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Lobe Sciences OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Lobe Sciences's OCF Margin for the fiscal year that ended in Aug. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Aug. 2025 )/Revenue (A: Aug. 2025 )
=-0.882/0
= %

Lobe Sciences's OCF Margin for the quarter that ended in Feb. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Feb. 2026 )/Revenue (Q: Feb. 2026 )
=-1.276/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Lobe Sciences (FRA:LOBE) has a OCF Margin % of 0.00% as of Feb. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Lobe Sciences and its competitors. According to the industry distribution chart, Lobe Sciences ranks #999999 out of 960 companies in the Biotechnology industry.
Is Lobe Sciences' OCF Margin % too high?
Lobe Sciences' current OCF Margin % is 0.00%. Based on the distribution chart, Lobe Sciences ranks #999999 out of 960 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Lobe Sciences' OCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Lobe Sciences ranks #999999 out of 960 companies for OCF Margin %. This places Lobe Sciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Lobe Sciences and its competitors. Lobe Sciences's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lobe Sciences stock overvalued right now?
Lobe Sciences (FRA:LOBE) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Lobe Sciences (FRA:LOBE), the current OCF Margin % is 0.00% as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lobe Sciences Business Description

Other Exchanges LOBEF:USALOBE:Canada
Address 1771 Robson Street, No. 1614, Vancouver, BC, CAN, V6G 3B7
Lobe Sciences Ltd is a biopharmaceutical company focused on using lipid technology that develop therapies for orphan and rare diseases. It commercializes Altemia MF, a medical food intended to address nutritional deficiencies associated with sickle cell disease. Through its subsidiaries, the company also holds a majority interest in the development of Conjugated Psilocin for potential use in neurological and psychiatric indications. The company operates in one reportable segment, being the biopharmaceutical development of new medicines.